Skip to main content

Table 3 Ejection Fraction Data for Participants Hospitalized with Heart Failure*

From: Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone

  Chlorthalidone Treatment Group Doxazosin Treatment Group Total
Participants with hospitalized heart failure 245 296 541
Hospitalized heart failure participants reviewed 134 144 278
Total reviewed heart failure participants with quantitative ejection fractions 46 59 105
   By cardiac catheterization (%) 11 (23.9) 21 (35.6) 32 (30.5)
   By echocardiogram (%) 33 (71.7) 37 (62.7) 70 (66.7)
   Method not given (%) 2 (4.3) 1 (1.7) 3 (2.9)
Ejection fraction (%)    
1–30% 15 (32.6) 27 (45.8) 42 (40.0)
31–40% 14 (30.4) 14 (23.7) 28 (26.7)
41–50% 9 (19.6) 7 (11.9) 16 (15.2)
51–60% 3 (6.5) 10 (16.9) 13 (12.4)
>60% 5 (10.9) 1 (1.7) 6 (5.7)
  1. *Evaluation of documentation for ejection fractions was completed in July, 1999, 6 months prior to the decision to discontinue the doxazosin arm of ALLHAT. Total numbers of events and participants with heart failure in Table 3 are based on data at the time of review. Event documentation which referred to ejection fraction measurements but which did not provide numeric values was excluded from this tally. Ejection fraction for a participant is based upon the earliest post-randomization heart failure hospitalization with quantitative ejection fraction information provided.